Mike Davies presents at the “Adaptive Designs in Clinical Trials” conference

Mike Davies, CMO and Co-founder, presented at the SMI Conference “Adaptive Designs in Clinical Trials” in London on 4th April 2017.

In it, Mike described how Blueberry Therapeutics utilises adaptive clinical trial designs for its lead compound, BB2603, a novel nanoparticle formulation of terbinafine, to treat onychomycosis and tinea pedis.

 

2017-05-10T10:46:33+00:00 April 4th, 2017|